Panelists discuss how disease progression monitoring requires integrating multiple data points including symptoms, six-minute walk tests, biomarkers like BNP/NT-proBNP, and imaging studies, with risk stratification tools helping guide treatment decisions while considering individual patient characteristics.
Barriers to Early Detection and Diagnosis
Common barriers to early PAH detection include the nonspecific nature of symptoms, which often leads to misattribution to more common conditions like deconditioning or asthma. Primary care physicians frequently prescribe asthma inhalers as initial treatment, which is reasonable given the rarity of PAH compared to common respiratory conditions. However, the lack of improvement with standard treatments should prompt deeper investigation and consideration of alternative diagnoses.
The complexity of PAH evaluation presents another significant barrier, as diagnosis requires a multi-layered assessment rather than simple testing procedures. Unlike straightforward conditions diagnosed through chest X-rays or basic tests, PAH evaluation involves comprehensive testing to determine disease classification among five different pulmonary hypertension groups. This complexity necessitates expertise not only in ordering appropriate tests but also in high-quality interpretation of results.
Timely referral to expert care centers represents a critical factor in overcoming diagnostic barriers. Specialized pulmonary hypertension centers possess the experience and resources necessary for comprehensive evaluation and accurate diagnosis. Educational initiatives targeting community practitioners and primary care physicians, combined with emphasis on screening high-risk populations such as patients with connective tissue diseases, can help reduce diagnostic delays and improve patient outcomes.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More